Stockscreener 앱 받기
5.03
1.21%
0.06
전일 마감가:
$4.97
열려 있는:
$4.96
하루 거래량:
2.66M
Relative Volume:
0.55
시가총액:
$1.54B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
100.60
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
-0.59%
1개월 성능:
-8.71%
6개월 성능:
+20.62%
1년 성능:
-27.10%
1일 변동 폭
$4.95
$5.07
1주일 범위
$4.93
$5.145
52주 변동 폭
$3.3812
$7.07
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.03 | 1.53B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-10-10 | 개시 | Leerink Partners | Outperform |
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will MannKind Corporation stock outperform value stocksMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Is MannKind Corporation (NNFN) stock a contrarian opportunityPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Why MannKind Corporation (NNFN) stock attracts wealthy investorsTrend Reversal & Safe Entry Momentum Tips - newser.com
What momentum indicators show for MannKind Corporation stock2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
How MannKind Corporation stock performs after earningsJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
How MannKind Corporation (NNFN) stock trades under stagflationMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Is MannKind Corporation (NNFN) stock attractive post correction2025 Fundamental Recap & Verified Short-Term Plans - newser.com
Is MannKind Corporation stock cheap compared to fundamentalsShare Buyback & Safe Swing Trade Setups - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights - Investing.com India
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Can MannKind Corporation (NNFN) stock sustain double digit ROE2025 Price Momentum & Fast Exit Strategy with Risk Control - newser.com
Is MannKind Corporation (NNFN) stock a safe buy pre earnings2025 Top Decliners & AI Driven Stock Reports - newser.com
Technical signs of recovery in MannKind CorporationTrade Ideas & Stepwise Trade Signal Implementation - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Buys Shares of 67,889 MannKind Corporation $MNKD - MarketBeat
Will MannKind Corporation stock maintain dividend yieldQuarterly Performance Summary & Daily Market Momentum Tracking - newser.com
Insider Selling: MannKind (NASDAQ:MNKD) EVP Sells $94,448.31 in Stock - MarketBeat
Can swing trading help recover from MannKind Corporation losses - newser.com
Connor Clark & Lunn Investment Management Ltd. Decreases Position in MannKind Corporation $MNKD - MarketBeat
Insider Sell: Sanjay Singh Sells Shares of MannKind Corp (MNKD) - GuruFocus
Will MannKind Corporation continue its uptrend2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Mannkind EVP Singh sells $94k in stock By Investing.com - Investing.com Canada
Mannkind EVP Singh sells $94k in stock - Investing.com
MannKind (NASDAQ:MNKD) Now Covered by Leerink Partners - MarketBeat
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wells Fargo & Company - MarketBeat
Visual analytics tools that track MannKind Corporation performanceMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Can MannKind Corporation (NNFN) stock attract analyst upgradesJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - newser.com
MannKind (Nasdaq: MNKD) to present at Jefferies; webcast Nov. 19 at 6:30 am ET - Stock Titan
RBC Capital Maintains MannKind (MNKD) Outperform Recommendation - Nasdaq
MannKind (NASDAQ:MNKD) Shares Gap DownHere's What Happened - MarketBeat
RBC Capital Adjusts MNKD Price Target, Maintains Outperform Rati - GuruFocus
Wells Fargo Lowers Price Target for MannKind (MNKD) Amid Overwei - GuruFocus
MannKind stock price target lowered to $7.50 at RBC on NTM trial failure - Investing.com
MannKind stock falls after discontinuing Phase 3 NTM lung disease trial - Investing.com Canada
Danbury biopharma firm halts late-stage drug trial after disappointing results - Hartford Business Journal
MannKind Corp. Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
MannKind (MNKD) Halts Phase 3 Trial Due to Ineffectiveness - GuruFocus
MannKind (MNKD) Halts MNKD-101 Trial, Stock Falls 10% - GuruFocus
MannKind discontinues Phase 3 trial for MNKD-101 in NTM lung disease - Investing.com Canada
MannKind (MNKD) Halts Phase 3 Trial for Lung Disease Treatment - GuruFocus
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):